Wan-Jun Kim
Fortuna: - $ al 31/07/2026
Fortuna: - $ al 31/07/2026
Wan-Jun Kim is currently Chief Financial Officer & Director at Imbiologics Corp.
since 2024.
Formerly, Mr. Kim was Chief Financial Officer at KoBioLabs, Inc. Education includes undergraduate and graduate degrees from Korea University.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
IMBIOLOGICS CORP. -.--% | 10/06/2026 | 0 ( -.--% ) | - $ | 31/07/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| IMBIOLOGICS CORP. | Director Financiero/CFO | 12/11/2024 |
| Empresas | Cargo | Fin |
|---|---|---|
| KOBIOLABS, INC | Director Financiero/CFO | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 3 |
|---|---|
Korea University
Korea University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
KoBioLabs, Inc.
KoBioLabs, Inc. BiotechnologyHealth Technology Researches and develops microbiome | Health Technology |
Imbiologics Corp.
Imbiologics Corp. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops antibodies for autoimmune diseases | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.